Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Review ArticleMINIREVIEWS

Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor

Brian D. Hudson, Terence E. Hébert and Melanie E. M. Kelly
Molecular Pharmacology January 2010, 77 (1) 1-9; DOI: https://doi.org/10.1124/mol.109.060251
Brian D. Hudson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terence E. Hébert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie E. M. Kelly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Seven-transmembrane G protein-coupled receptors (GPCRs) represent the single largest family of cell surface receptors. Signaling through these receptors is controlled by changes in the conformation of the receptor from inactive to active conformations, which in turn lead to the activation of multiple downstream signaling pathways. To facilitate greater diversity in signaling responses, many of these receptors are capable of adopting several distinct active conformations, in which each couples preferentially to its own set of downstream signaling partners. Because these unique signaling responses result from specific receptor active conformations, GPCR signaling may be directed toward these selective responses through either strength-of-signal effects resulting from partial agonism or through biased agonism and functional selectivity, resulting from the selective stabilization of one active conformation over the others. This review uses the CB1 cannabinoid receptor as a specific example to highlight the contribution of two important aspects of GPCR function—orthosteric ligand binding and receptor heterodimerization—toward directed GPCR signaling.

Footnotes

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    doi:10.1124/mol.109.060251

  • ABBREVIATIONS:

    GPCR
    G protein-coupled receptor
    2-AG
    2-arachydonylglycerol
    AEA
    N-arachidonoylethanolamine or anandamide
    β2AR
    β2 adrenergic receptor
    CNS
    central nervous system
    G protein
    guanine nucleotide binding protein
    MAEA
    (R)-methanandamide
    THC
    (−-)trans-Δ9-tetrahydrocannabinol
    WIN
    WIN 55,212-2
    ERK
    extracellular signal-regulated kinase
    ICI 118
    551, (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol.

    • Received August 11, 2009.
    • Accepted October 15, 2009.
  • © 2010 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 77 (1)
Molecular Pharmacology
Vol. 77, Issue 1
1 Jan 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleMINIREVIEWS

Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor

Brian D. Hudson, Terence E. Hébert and Melanie E. M. Kelly
Molecular Pharmacology January 1, 2010, 77 (1) 1-9; DOI: https://doi.org/10.1124/mol.109.060251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleMINIREVIEWS

Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor

Brian D. Hudson, Terence E. Hébert and Melanie E. M. Kelly
Molecular Pharmacology January 1, 2010, 77 (1) 1-9; DOI: https://doi.org/10.1124/mol.109.060251
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • The CB1 Cannabinoid Receptor
    • Ligand-Directed Signaling of CB1
    • Heterodimer-Directed CB1 Signaling
    • Allosteric Ligands of CB1 and Functional Selectivity
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanotransduction in Cancer
  • Intracellular mGlu5
  • NADPH Oxidases and Influenza Virus Infections
Show more Minireviews

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics